BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fouad SA, Mohamed NA, Fawzy MW, Moustafa DA. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma. Hepat Mon 2015;15:e30753. [PMID: 26500684 DOI: 10.5812/hepatmon.30753] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
2 Zhou N, Wang K, Fang S, Zhao X, Huang T, Chen H, Yan F, Tang Y, Zhou H, Zhu J. Discovery of a Potential Plasma Protein Biomarker Panel for Acute-on-Chronic Liver Failure Induced by Hepatitis B Virus. Front Physiol 2017;8:1009. [PMID: 29270132 DOI: 10.3389/fphys.2017.01009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
3 Li J, Chen X, Dai M, Huang S, Chen J, Dai S. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:543-53. [PMID: 28291627 DOI: 10.1016/j.clinre.2017.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sun T, Tang Y, Sun D, Bu Q, Li P. Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther 2018;11:8925-35. [PMID: 30573979 DOI: 10.2147/OTT.S186230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
5 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 2018;5:181006. [PMID: 30662724 DOI: 10.1098/rsos.181006] [Cited by in Crossref: 124] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
7 Hodeib H, ELshora O, Selim A, Sabry NM, El-Ashry HM. Serum Midkine and Osteopontin Levels as Diagnostic Biomarkers of Hepatocellular Carcinoma. Electron Physician 2017;9:3492-8. [PMID: 28243398 DOI: 10.19082/3492] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
8 Wang F, Liu H, Bai Y, Li H, Wang Z, Xu X. Performance of SPINK1 and SPINK1-based diagnostic model in detection of hepatocellular carcinoma. J Clin Lab Anal 2021;35:e24025. [PMID: 34569662 DOI: 10.1002/jcla.24025] [Reference Citation Analysis]
9 Zhang Y, Gao J, Bao Y, Liu Y, Tong Y, Jin S, Zhao Q. Diagnostic accuracy and prognostic significance of osteopontin in liver cirrhosis and hepatocellular carcinoma: a Meta-analysis. Biomarkers 2021;:1-9. [PMID: 34787036 DOI: 10.1080/1354750X.2021.2008009] [Reference Citation Analysis]
10 Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines 2021;9:159. [PMID: 33562077 DOI: 10.3390/biomedicines9020159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Caserza L, Casula M, Elia E, Bonaventura A, Liberale L, Bertolotto M, Artom N, Minetti S, Contini P, Verzola D, Pontremoli R, Viazzi F, Viviani GL, Bertolini S, Pende A, Pisciotta L, Montecucco F, Carbone F. Serum osteopontin predicts glycaemic profile improvement in metabolic syndrome: A pilot study. Eur J Clin Invest 2021;51:e13403. [PMID: 32918277 DOI: 10.1111/eci.13403] [Reference Citation Analysis]
12 Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for Hepatocellular Carcinoma. Biomark Cancer. 2017;9:1-9. [PMID: 28469485 DOI: 10.1177/1179299x16684640] [Cited by in Crossref: 61] [Cited by in F6Publishing: 41] [Article Influence: 12.2] [Reference Citation Analysis]
13 Wang C, He M, Peng J, Li S, Long M, Chen W, Liu D, Yang G, Zhang L. Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Cytokine. 2020;125:154837. [PMID: 31514105 DOI: 10.1016/j.cyto.2019.154837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lee SH, Park JW, Woo SH, Go DM, Kwon HJ, Jang JJ, Kim DY. Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice. Oncotarget 2016;7:87219-31. [PMID: 27888617 DOI: 10.18632/oncotarget.13529] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
15 Sobhy A, Fakhry M M, A Azeem H, Ashmawy AM, Omar Khalifa H. Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus. J Investig Med 2019;67:681-5. [PMID: 30385593 DOI: 10.1136/jim-2018-000840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020;15:e0228857. [PMID: 32053643 DOI: 10.1371/journal.pone.0228857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
17 Dadfar SMM, Sekula-Neuner S, Trouillet V, Liu HY, Kumar R, Powell AK, Hirtz M. Evaluation of click chemistry microarrays for immunosensing of alpha-fetoprotein (AFP). Beilstein J Nanotechnol 2019;10:2505-15. [PMID: 31921529 DOI: 10.3762/bjnano.10.241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, Filipponi F, Basta G, Gastaldelli A, Del Ry S. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up. Cytokine 2017;99:59-65. [PMID: 28711012 DOI: 10.1016/j.cyto.2017.07.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]